| Drug Type Small molecule drug | 
| Synonyms (+)-ABX | 
| Target | 
| Action inhibitors | 
| Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors), PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC27H24O7 | 
| InChIKeyMDUGEFRGUDVHQH-XNMGPUDCSA-N | 
| CAS Registry149466-04-6 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Preclinical | China  | 23 Apr 2024 | 





